Salivary expression of lncRNA DQ786243 and IL-17 in oral lichen planus: case–control study

Abstract

Background A growing number of studies has investigated IL-17 in OLP. However, its exact role and interactions are not fully determined. In addition, the literature investigating its salivary expression is limited. The scarcity in the literature studying lncRNAs was noticed, particularly with regards to correlating them with cytokines in OLP. In the current study, the salivary expression of lncRNA DQ786243 and IL-17 was assessed among different forms of OLP. Methods The study included 52 participants in four equal groups: reticular OLP, erythematous OLP, ulcerative OLP, and control group. All eligible OLP patients underwent conventional oral examination, along with basic charting of their demographic data, pain intensity using a visual analogue scale, and clinical evaluation using the Thongprasom et al. scale. The salivary expression of lncRNA DQ786243 and IL-17 was evaluated for all participants using qRT-PCR. Unstimulated whole saliva samples were used. Data were analyzed for statistical significance. Results No statistically significant difference was observed when comparing the mean age and gender distribution of the studied groups. A statistically significant difference was detected when comparing pain and clinical scores in the three OLP forms. The highest expression of both salivary biomarkers was noticed in ulcerative OLP, followed by erythematous OLP and reticular OLP, then the controls, with a significant difference between the studied groups. Upon comparing the salivary expression of DQ786243 in ulcerative and erythematous OLP, no significant difference was detected. No significant difference was detected when comparing salivary expression of IL-17 in erythematous OLP to the other OLP forms. Conclusions The salivary expression of lncRNA DQ786243 and IL-17 was upregulated in OLP compared to healthy individuals. Besides, their expression increased when the severity of OLP was at its highest level in ulcerative OLP. There was a positive correlation between DQ786243 and IL-17. Trial registration The protocol was registered at ClinicalTrials.gov (NCT04503824). The date of registration is 07/08/2020.

A Systematic Review of Interleukin-17 in Oral Lichen Planus: From Etiopathogenesis to Treatment

“…88 Several studies showed significant upregulation of IL-17 in tissue, serum, and saliva samples of OLP patients compared with healthy controls. 2,9,11,15,16,23,32,44,78,79,82,[88][89][90][91] Considering T-cell-mediated immune response in pathogenesis of OLP, presence of IL-17 and its regulatory role in OLP is not surprising. It participates in the pathogenesis of OLP through the following mechanisms: (I) reinforcement of T lymphocyte reactions and production of inflammatory mediators such as IL-6, IL-8, and IL-1B, 15,78 (II) regulation of production of matrix metalloproteinase-9 (that breaks type IV collagen leading to impairment of the basement membrane and apoptosis of keratinocytes), 92,93 (III) reduction in diversity of oral bacteria (providing an opportunity for opportunistic pathogens to stimulate the innate and acquired immune system and lead to disease flare-up), 88 (IV) and increased hypersensitivity reactions (through degranulation of mast cells).89 Th17 cells are imperative to coordinate the immune responses elicited by extracellular bacteria and fungi.…”

A Transcriptomic Analysis to Identify Prevalent lncRNAs in Gingivobuccal Oral Cancer

“…Despite the presence of glaring evidence for lncRNA playing a critical role in the biological processes of human diseases, very few efforts have been made to identify their association with gingivobuccal cancer and assess their prognostic (2,5) . Furthermore the interest in the identification of lncRNA signatures in Gingivobuccal Squamous Cell Carcinoma (GBSCC) stems from the idea of identification of non-invasive biomarkers present in the saliva for early detection of oral cancer (6,7) .…”